Duran v. Obesity Research Institute

California Court of Appeal·Decided July 15, 2016·No. D067917·Published

Opinion

Filed 6/23/16; pub. order 7/15/16 (see end of opn.)

COURT OF APPEAL, FOURTH APPELLATE DISTRICT DIVISION ONE

STATE OF CALIFORNIA

FRED DURAN, D067917 Plaintiff and Respondent,

v. (Super. Ct. No.

37-2013-00048664-CU-BT-CTL)

OBESITY RESEARCH INSTITUTE, LLC et al.,

Defendants and Respondents;

DEMARIE FERNANDEZ et al., Objectors and Appellants.

APPEAL from a judgment and order of the Superior Court of San Diego County, John S. Meyer, Judge. Judgment and order reversed.

Bursor & Fisher, Scott A. Bursor, L. Timothy Fisher, Annick M. Persinger and Neal J. Deckant for Objectors and Appellants.

Nicholas & Tomasevic, Alex Tomasevic and Craig M. Nicholas for Plaintiff and Respondent.

Newport Trial Group, Scott J. Ferrell, David W. Reid; Gordon & Rees and Richard P. Sybert for Defendant and Respondent Obesity Research Institute, LLC.

Shook, Hardy & Bacon, Frank C. Rothrock, D. Susan Wiens and Paul B. La Scala for Defendant and Respondent Wal-Mart Stores, Inc.

Fred Duran filed a putative class action complaint against Obesity Research Institute, LLC (ORI) and Wal-Mart Stores, Inc. (Wal-Mart) (collectively, defendants). Duran alleges defendants falsely claimed that ORI's products, Lipozene and MetaboUp, have weight loss benefits. The court approved a claims-made settlement providing that class members submitting a claim without proof of purchase would receive $15, and those submitting receipt(s) would receive one refund of double the unit price paid. The settlement also provided that ORI would cease making certain assertions in product advertising. Defendants also agreed to not oppose a motion seeking $100,000 in attorney fees to class counsel.

In a class estimated to consist of between 400,000 and 600,000 consumers, 895 claims were submitted, in the total amount of $31,800. Assuming there were 500,000 class members, less than two-tenths of 1 percent (0.179 percent) submitted claims. Thus, the proposed settlement buys a nationwide release for the price of about six cents ($0.064) per class member. And for achieving this result, class counsel receive $100,000 in attorney fees—about 75 percent of the total amount paid.

Objectors, class members DeMarie Fernandez, Alfonso Mendoza, and Brian Horowitz (collectively, objectors) appeal, contending the settlement is the product of collusion. Objectors assert the class did not receive sufficient notice of settlement, and

the settlement is unreasonable and inadequate. They also contend the attorney fee award is excessive.

As we explain, the downloadable online claim form, a part of the class notice of settlement, misrepresents three material terms of the settlement: (1) the amount of payment to class members is misstated; (2) the claim form refers to Hydroxycut products, which are not involved in this case; and (3) a Civil Code section 1542 release was included in the claim form, although at the preliminary approval hearing the court stated it would not approve such a release.

After we called these errors in the claim form to counsels' attention (no one raised this issue in the trial court) and requested supplemental briefing, class counsel and defendants candidly conceded, "[T]he class members were not clearly informed of what the terms of the settlement were, and what benefits they would receive and what claims they would release if they submitted a claim." Nevertheless, class counsel and defendants contend the trial court's determination that the settlement is fair and reasonable should be affirmed, and the case should be remanded only to decide the "details and logistics" of giving corrected class notice.

Remand cannot be limited to giving a corrected class notice. The judgment must be reversed because the class notice failed in its fundamental purpose—to apprise class members of the terms of the proposed settlement. The erroneous notice injected a fatal flaw into the entire settlement process and undermines the court's analysis of the settlement's fairness. (See Petrone v. Veritas Software Corp. (In re Veritas Software Corp. Sec. Lit.) (9th Cir. 2007) 496 F.3d 962, 972 (Veritas).)

Although reversal on this ground makes it unnecessary to consider other issues objectors raise, in the interests of judicial economy, we also discuss two issues that will likely arise on remand: (1) the manner of giving class notice of settlement, and (2) whether the trial court properly considered the injunctive relief portion of the settlement as "the most important part" in determining its reasonableness.

FACTUAL AND PROCEDURAL BACKGROUND A. Duran's Putative Class Action Complaint In May 2013 Duran filed a putative class action complaint against ORI and Wal-

Mart for alleged violations of the Consumers Legal Remedies Act (CLRA) (Civ. Code, § 1750 et seq.), Unfair Competition Law (Bus. & Prof. Code, § 17200 et seq.), False Advertising Law (Bus. & Prof. Code, § 17500 et seq.) and other state law claims. Duran filed the action on behalf of himself and "[a]ll persons, nationwide" who purchased ORI diet products for personal use "after August 10, 2012 until the date notice is disseminated."

Duran's complaint identifies ORI's products as Lipozene and MetaboUp. He alleged ORI "markets and sells" these products as a "'weight-loss breakthrough'" that is "'clinically proven to help you lose weight and pure body fat'" and represents these products "'can help you lose weight without a change in lifestyle.'" Duran alleged these representations were false and misleading and that "Lipozene is not, in fact, effective for weight control." He alleged that ORI's promises and representations that its diet products are "clinically proven and guaranteed weight loss miracle are false and have been used to unfairly deceive millions of consumers into buying" ORI's products. Duran alleged that

Wal-Mart "promotes and disseminates" ORI's "deceptive advertising claims by carrying and distributing the Lipozene and/or MetaboUp products."

B. Motion for Class Certification In July 2013 Duran filed a motion for class certification, set for hearing in December 2013. In seeking class certification, class counsel stated, "Lipozene and MetaboUp are not, in fact, 'clinically proven' to be weight-loss miracle pills and Defendants have simply swindled consumers out of millions of dollars based on a uniform set of misrepresentations that make up a marketing story."

C. The First Motion for Preliminary Approval In November 2013—before the class certification motion was heard—Duran and ORI jointly moved for preliminary approval of settlement. The settlement included certification of a settlement class defined as "all persons in the United States who purchased ORI's products during the Class Period for personal or household use . . . ."

The settlement provided that class members submitting a valid claim without proof of purchase would receive $15, and those submitting proof of purchase would receive double the unit price paid (between $28 and $68), limited to one such refund. The settlement agreement provides that claims will be paid from a "Non-Reversionary Fund."1

1 A "claims-made" settlement, as here, is one that does not have a fixed settlement fund, but rather provides the defendant will pay claims of class members who file them. (Rubenstein, Newberg on Class Actions (5th ed. 2014) § 13:7, p. 287 (Newberg).) Such settlements may promise far more than they deliver because the claiming rate is notoriously low. (See Sullivan v. DB Invs., Inc. (3d Cir. 2011) 667 F.3d 273, 329, fn. 60

The settlement also provided that ORI will establish a "Reserved Fund" of $500,000 to pay the costs of administration, notice, incentive awards and attorney fees. This fund would be retained "internally" by ORI. Any reserved amounts not used to pay these expenses would "cease to be internally reserved by ORI" when the judgment is final.

Free access — add to your briefcase to read the full text and ask questions with AI

Duran v. Obesity Research Institute, (Cal. Ct. App. 2016).

Duran v. Obesity Research Institute (Duran v. Obesity Research Institute) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
Brandwein v. Butler CA4/1
218 Cal. App. 4th 1485 (California Court of Appeal, 2013)
In Re Veritas Software Corp. Securities Litigation
496 F.3d 962 (Ninth Circuit, 2007)
Cartt v. Superior Court
50 Cal. App. 3d 960 (California Court of Appeal, 1975)
WOODWARD PARK HOMEOWNERS v. City of Fresno
58 Cal. Rptr. 3d 102 (California Court of Appeal, 2007)
Wershba v. Apple Computer, Inc.
110 Cal. Rptr. 2d 145 (California Court of Appeal, 2001)
Consumer Cause, Inc. v. Mrs. Gooch's Natural Food Markets, Inc.
25 Cal. Rptr. 3d 514 (California Court of Appeal, 2005)
Cho v. Seagate Technology Holdings, Inc.
177 Cal. App. 4th 734 (California Court of Appeal, 2009)
Cellphone Termination Fee Cases
186 Cal. App. 4th 1380 (California Court of Appeal, 2010)
Dunk v. Ford Motor Co.
48 Cal. App. 4th 1794 (California Court of Appeal, 1996)
Tsemetzin v. Coast Federal Savings & Loan Ass'n
57 Cal. App. 4th 1334 (California Court of Appeal, 1997)
Sylvester v. Cigna Corp.
369 F. Supp. 2d 34 (D. Maine, 2005)
In Re Motorsports Merchandise Antitrust Litigation
112 F. Supp. 2d 1329 (N.D. Georgia, 2000)
Luckey v. Superior Court
228 Cal. App. 4th 81 (California Court of Appeal, 2014)
Salvatore Gallucci v. Henry Gonzales
603 F. App'x 533 (Ninth Circuit, 2015)
Sullivan v. DB Investments, Inc.
667 F.3d 273 (Third Circuit, 2011)
Carlough v. Amchem Products, Inc.
158 F.R.D. 314 (E.D. Pennsylvania, 1993)